Literature DB >> 32089060

Silencing of PTEN inhibits the oxidative stress damage and hippocampal cell apoptosis induced by Sevoflurane through activating MEK1/ERK signaling pathway in infant rats.

Tiejun Liu1, Xiaoliu Dong2, Bin Wang3, Shubo Zhang1, Jing Bai1, Wei Ma1, Xiaojing Zhao1, Xiaotao Wang1.   

Abstract

Phosphatase and tensin homolog (PTEN) is a suppressive player in tumor but its concrete role in oxidative stress (OS) damage and cell apoptosis remains much exploration. Thus, this study is conducted to explore the participation of PTEN and its mechanisms in OS damage and cell apoptosis in hippocampal cells.Infant rats were grouped into normal, Sevo, Sevo + si-negative control (NC), Sevo + si-PTEN and Sevo + si-PTEN + PD (MEK1/ERK signaling pathway inhibitor) groups. Infant hippocampal cells were grouped into blank, Sevo, Sevo + si-NC, Sevo + si-PTEN and Sevo + si-PTEN + PD groups. The expressions of PTEN and MEK1/ERK signaling pathway-related proteins were determined. OS-related indices in hippocampal tissues and cells were detected. Cell apoptosis was detected by flow cytometry.Sevoflurane up-regulated PTEN expression and silencing of PTEN activates MEK1/ERK signaling pathway in hippocampal tissues and cells of infant rats. Silencing of PTEN alleviated hippocampal tissue pathological status and inhibited sevoflurane-induced cell apoptosis in hippocampal tissues of infant rats. Silencing of PTEN alleviated OS damage in hippocampal tissues of infant rats. Silencing of PTEN inhibited sevoflurane-induced apoptosis after OS damage in hippocampal cells of infant rats. Silencing of PTEN reduced sevoflurane-induced OS damage in hippocampal cells of infant rats.Our study demonstrates that PTEN silencing inhibits the OS damage and cell apoptosis in hippocampal cells induced by Sevoflurane through activating MEK1/ERK signaling pathway in infant rats.

Entities:  

Keywords:  MEK1/ERK signaling pathway; Oxidative damages; PTEN; apoptosis; gene silencing; sevoflurane

Mesh:

Substances:

Year:  2020        PMID: 32089060      PMCID: PMC7145332          DOI: 10.1080/15384101.2020.1717041

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  29 in total

1.  The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.

Authors:  Toshio Shimizu; Anthony W Tolcher; Kyriakos P Papadopoulos; Muralidhar Beeram; Drew W Rasco; Lon S Smith; Shelly Gunn; Leslie Smetzer; Theresa A Mays; Brianne Kaiser; Michael J Wick; Cathy Alvarez; Aracely Cavazos; Gina L Mangold; Amita Patnaik
Journal:  Clin Cancer Res       Date:  2012-01-19       Impact factor: 12.531

2.  One-year outcome of the sevoflurane in acute myocardial infarction randomized trial.

Authors:  Shahar Lavi; Mistre Alemayehu; David McCarty; James Warrington; Ronit Lavi
Journal:  Can J Anaesth       Date:  2015-08-22       Impact factor: 5.063

Review 3.  Reactive oxygen/nitrogen species and their functional correlations in neurodegenerative diseases.

Authors:  Mahesh Ramalingam; Sung-Jin Kim
Journal:  J Neural Transm (Vienna)       Date:  2012-01-04       Impact factor: 3.575

4.  Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness.

Authors:  Shuhua Yue; Junjie Li; Seung-Young Lee; Hyeon Jeong Lee; Tian Shao; Bing Song; Liang Cheng; Timothy A Masterson; Xiaoqi Liu; Timothy L Ratliff; Ji-Xin Cheng
Journal:  Cell Metab       Date:  2014-03-04       Impact factor: 27.287

5.  Lifetime cancer risks in individuals with germline PTEN mutations.

Authors:  Min-Han Tan; Jessica L Mester; Joanne Ngeow; Lisa A Rybicki; Mohammed S Orloff; Charis Eng
Journal:  Clin Cancer Res       Date:  2012-01-15       Impact factor: 12.531

6.  Differences in myocardial PTEN expression and Akt signalling in type 2 diabetic and nondiabetic patients undergoing coronary bypass surgery.

Authors:  Baohua Wang; Koen Raedschelders; Jayant Shravah; Yu Hui; Hajieh G Safaei; David D Y Chen; Richard C Cook; Guy Fradet; Calvin L Au; David M Ansley
Journal:  Clin Endocrinol (Oxf)       Date:  2011-06       Impact factor: 3.478

7.  Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer.

Authors:  Ziqing Wu; Benfu He; Jincan He; Xiangming Mao
Journal:  Prostate       Date:  2012-10-11       Impact factor: 4.104

8.  Roles for PI3K/AKT/PTEN Pathway in Cell Signaling of Nonalcoholic Fatty Liver Disease.

Authors:  Satoru Matsuda; Mayumi Kobayashi; Yasuko Kitagishi
Journal:  ISRN Endocrinol       Date:  2013-01-30

9.  Inhibiting PTEN protects hippocampal neurons against stretch injury by decreasing membrane translocation of AMPA receptor GluR2 subunit.

Authors:  Yuan Liu; Li Wang; Zai-yun Long; Ya-min Wu; Qi Wan; Jian-xin Jiang; Zheng-guo Wang
Journal:  PLoS One       Date:  2013-06-17       Impact factor: 3.240

Review 10.  Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Giuseppe Montalto; Melchiorre Cervello; Ferdinando Nicoletti; Paolo Fagone; Grazia Malaponte; Maria C Mazzarino; Saverio Candido; Massimo Libra; Jörg Bäsecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Michele Milella; Agostino Tafuri; Lucio Cocco; Camilla Evangelisti; Francesca Chiarini; Alberto M Martelli
Journal:  Oncotarget       Date:  2012-09
View more
  1 in total

1.  Activation of PTEN/P13K/AKT Signaling Pathway by miRNA-124-3p-Loaded Nanoparticles to Regulate Oxidative Stress Attenuates Cardiomyocyte Regulation and Myocardial Injury.

Authors:  Yuan Cheng; Qing He; Na Li; Mengdi Luo
Journal:  Oxid Med Cell Longev       Date:  2022-10-11       Impact factor: 7.310

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.